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Summary 
Background: Vitamin D deficiency is repeatedly reported in
colorectal cancer (CRC). Since cholesterol and vitamin D
share common precursor 7-dehydrocholesterol (7-DHC), it
would be important to explore the associations of key vita-
min D metabolites and serum lipid parameters in patients
with high and low grade CRC. The aim of this study was to
analyze relationships between serum 25(OH)D3,
24,25(OH)2D3 and 7-DHC levels and serum lipids in
patients with CRC, and to evaluate their potential for pre-
diction of risk for development of high grade CRC. 
Methods: We recruited 82 patients CRC and 77 controls.
7-DHC, 25(OH)D3 and 24,25(OH)2D3 were quantified by
LC-MS/MS methods.
Results: 7-DHC, 25(OH)D3 and vitamin D metabolic ratio
(VDMR) were significantly lower in CRC patients than in
control group (P<0.001, P<0.010, P<0.050 and
P<0.050, respectively). 25(OH)D3 levels were higher in
patients with grade I CRC when compared to grade II
(P<0.050). All vitamin D metabolites positively correlated
with total cholesterol (TC) concentration in CRC patients.
25(OH)D3 was significant predictor of increased CRC risk
(P<0.010). After adjustment for TC concentration,
25(OH)D3 lost its predictive abilities. However, 25(OH)D3
remained significant predictor of poorly differentiated type
of cancer (P<0.050).
Kratak sadr`aj
Uvod: Deficijencija vitamina D je u~estalo javlja kod obo -
lelih od kolorektalnog karcinoma (CRC). Kako holesterol i
vitamin D dele zajedni~ki prekursor 7-dehidroholesterol (7-
DHC), bilo bi zna~ajno ispitati povezanost klju~nih meta -
bolita vitamin D i serumskih lipidnih parametara kod paci-
jenata sa CRC klasifikovanih na osnovu gradusa. U ovom
radu ispitivali smo odnos izme|u serumskih koncentracija
25(OH)D3, 24,25(OH)2D3 and 7-DHC i serumskih lipida
kod pacijenata sa CRC, kao i doprinos metabolita vitamina
D u predikciji rizika za nastanak CRC visokog gradusa. 
Metode: U studiji su u~estvovala 82 pacijenta sa CRC i 77
zdravih ispitanika. 7-DHC, 25(OH)D3 i 24,25(OH)2D3 su
kvantifikovani pomo}u metode LC-MS/MS.
Rezultati: 7-DHC, 25(OH)D3 i odnos metabolita vitamina
D (VDMR) su bili zna~ajno ni`i kod pacijenata sa CRC u
odnosu na kontrolnu grupu (P<0,001, P<0,010, P<0,050
i P<0,050, redom). Koncentracije 25(OH)D3 su bile vi{e
kod pacijenata sa gradusom I u odnosu na pacijente sa
gradusom II (P<0,050). Svi metaboliti vitamina D su pozi-
tivno korelirali sa ukupnim holesterolom kod pacijenata sa
CRC. 25(OH)D3 je bio zna~ajan prediktor pove}anog rizika
za nastanak CRC (P<0,010). Nakon korekcije za koncen-
traciju ukupnog holesterola, 25(OH)D3 je izgubio predik-
tivni zna~aj. Me|utim, 25(OH)D3 je ostao zna~ajan predik-
tor slabo diferenciranog karcinoma (P<0,050).
List of abbreviations: CRC, colorectal cancer; 7-DHC, 7-dehy-
drocholesterol; VDMR, vitamin D metabolic ratio; DHCR7, 7-
DHC-reductase; BMI, body mass index; TC, total cholesterol;
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-densi-
ty lipoprotein cholesterol; TG, triglycerides; VDBP, vitamin D
binding protein; MTBE, methyl-tert-buthyl ether; MRM, multi-
ple-reaction-monitoring; MMI/APCI, multi-mode ionization/
atmo spheric pressure chemical ionization; OR, odds ratio; CI,
confidence interval.
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Introduction
Broadly recognized prevalence of vitamin D defi-
ciency in patients with colorectal cancer (CRC) direct-
ed scientific research towards the investigation of its
role during the onset and progression of this malig-
nancy. Anticancerous effects of vitamin D are well
known and include induction of anti-inflammatory,
anti-oxidative, anti-proliferative, anti-apoptotic and
pro-differentative properties in both normal and
malignant cells (1, 2). Yet, in spite of numerous epi-
demiological, clinical and interventional studies, no
definitive conclusions are drawn regarding the useful-
ness of vitamin D treatment in CRC (3). Furthermore,
a recent Mendelian randomization study has demon-
strated a lack of causality between genetically deter-
mined lower levels of vitamin D and CRC risk (4), sug-
gesting that further research should rather focus on
mechanisms that can alter vitamin D metabolism and
consequently, its effects in CRC. 
Many confounding factors, including sunlight
exposure, obesity, body-mass index and lipid status
can affect vitamin D level (5, 6). The relationship of
vitamin D with serum lipids can be particularly impor-
tant, considering that 7-dehydrocholesterol (7-DHC)
is a direct precursor of cholesterol, but also a direct
precursor of vitamin D synthesis in the skin. It has
been hypothesized that this metabolite and the activ-
ity of enzyme 7-DHC-reductase (DHCR7) might be
critical points in determining both cholesterol and
vitamin D levels (7), but this issue is insufficiently
explored in CRC. 
Metabolism of vitamin D is complex and
includes several intermediate compounds that are
proposed as markers of its status in the organism.
Although without biological activity, 25-hydroxyvita-
min D (25(OH)D3) is generally accepted as a reliable
marker of vitamin D status (8). However, recent evi-
dences have emphasized 24,25-dihydroxyvitamin D
(24,25(OH)2D3), a catabolic product with negligible
biological activity, as a promising marker for predic-
tion of vitamin D deficiency and several associated
pathological conditions (9). Accordingly, the ratio
between 25(OH)D3 and 24,25(OH)2D3, or vitamin
D metabolite ratio (VDMR) might provide more accu-
rate insight into vitamin D status and more precise
prediction of possible effects of disturbed vitamin D
levels (10). However, there is scarce data regarding
the usefulness of VDMR in CRC patients. 
The goal of this study was to estimate serum
25(OH)D3 levels and concentrations of 7-DHC and
24,25(OH)2D3 in patients with CRC. We analyzed
mutual relationship between these metabolites and
evaluated their predictive abilities, as well as possible
usefulness in prediction of CRC risk. Additionally, we
were interested in evaluation of the associations




For this study, we recruited 82 patients with first
time diagnosed CRC. Study participants were selected
from a larger cohort of 126 patients from the Clinic
for General Surgery, Military Medical Academy in
Belgrade, who were involved in larger research proj-
ect investigating lipid status, redox balance and
inflammatory markers in CRC (11, 12). Inclusion cri-
teria for participating in the study were: pathohisto-
logical confirmation of CRC, absence of other malig-
nant diseases or non-malignant systemic diseases of
bowel, kidney and liver, no use of hypolipidemic ther-
apy, no use of vitamin D supplements and no use of
neoadjuvant chemotherapy. After exclusion of sub-
jects with incomplete clinical or laboratory data, the
final patient’s group consisted of 82 participants.
Blood samples were taken immediately before surgi-
cal procedure. After an overnight fasting, blood sam-
ples were collected to EDTA plasma and serum evac-
uating tubes. Following the separation of serum and
plasma, aliquots were frozen and stored at -80°C for
further analysis. 
Tumor grades were defined according to patho-
histological findings as: grade I (well differentiated
tumor), grade II (moderately differentiated tumor)
and grade III (poorly differentiated tumor). CRC grade
I was diagnosed in 31.6%, grade II in 53.2% and
grade III in 15.2% of patients. For control group, we
selected 78 healthy volunteers during their annual
medical check-up examinations. All participants in
control group had negative family anamnesis for CRC
Conclusions: We found significant positive association
between vitamin D status and serum total cholesterol.
Although low 25(OH)D3 was found to be a significant risk
factor for CRC development, the obtained results primarily
suggest profound impact of cholesterol level on vitamin D
status in CRC. However, our results suggest that low
25(OH)D3 might independently contribute to development
of poorly differentiated tumor.
Keywords: 25-hydroxyvitamin D, 7-dehydrocholesterol,
24,25-dihydroxyvitamin D, total cholesterol, colorectal
cancer
Zaklju~ak: Utvr|ena je zna~ajna pozitivna korelacija iz me|u
statusa vitamina D i serumskih koncentracija ukupnog holes-
terola. Iako je uo~eno da je nizak 25(OH)D3 zna~ajan faktor
rizika za razvoj CRC, na{i rezultati upu}uju na dominantan
uticaj holesterola na status vitamina D kod ovih pacijenata.
Ipak, uo~eno je da niski nivoi 25(OH)D3 mogu nezavisno
doprineti razvoju slabo diferentovanih oblika CRC.
Klju~ne re~i: 25-hidroksivitamin D, 7-dehidroholesterol,
24,25-dihidroksivitamin D, ukupan holesterol, kolorektalni
karcinom
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and were free of any acute or chronic disease, or use
of any therapy which could affect lipid status or vita-
min D levels. 
Study participants were interviewed by using of
standardized questionnaire. Basic information on
patients’ anthropometric characteristics, life style
habits, use of any drugs and personal and family
anamnesis were collected. Body mass index (BMI)
was calculated as body weight (kg)/body height (m2). 
The study protocol was designed according to
the ethical principles of the Helsinki Declaration.
Local Ethics Committee carefully examined and
approved the study. All participants were informed
about the study aim and design and all of them
signed an informed consent prior to the involvement.
Methods
Total proteins and components of lipid profile,
including total cholesterol (TC), low-density lipopro-
tein cholesterol (LDL-C), high-density lipoprotein cho-
lesterol (HDL-C) and triglycerides (TG), were deter-
mined by routine laboratory methods on ILab 300+
automatic analyzer (Instrumentation Labo ra tory,
Diamond Diagnostics, USA). VDBP was quantified
using commercial ELISA assay for human samples,
VDBP Quantikine (R&D Systems).
Vitamin D metabolites and 7-DHC analyses
Analytical HPLC grade standards were used
for quantification of the 25(OH)D3, (24R)-
24,25(OH)2D3 (Sigma-Aldrich, St. Louis, USA).
Deuterated internal standards cholesterol-26,26,26,
27,27,27-d6,25(OH)D3 3-d6 and 1,25(OH)2D3 3-
d6 were obtained from Medical Isotopes (Pelham,
USA). 
KOH was purchased from POCH (Center Valley,
PA, USA), while ethanol, methanol, n-hexane, ethyl-
acetate, methyl-tert-buthyl ether (MTBE) and acetoni-
trile (HPLC grade) were obtained from Fisher
(Pittsburgh, PA, USA). 
The analysis of vitamin D status was conducted
using LC-MS/MS method developed and fully validat-
ed in our laboratory. Firstly, 500 mL of serum was
placed in a reaction tube and 2.5 mL of ice cold ace-
tonitrile were added to allow for the protein denatura-
tion to happen. This mixture was vigorously vortexed
for 30s, and centrifuged at 4000xg for 30 min. The
resulting supernatant was decanted into a clean reac-
tion tube, and evaporated under nitrogen stream to
the final volume of approx. 500 mL. Afterwards, the
1 mL of HPLC-grade water was added, alongside with
2 mL of MTBE: ethylacetate mixture (9: 1, v: v). The
tube was vigorously vortexed, and the upper layer was
transferred into clean vial and dried under nitrogen.
This extraction procedure was repeated three times in
total, and all the extracts were collected in the same
vial and evaporated to dryness. In the final step, the
extract was reconstituted in 20 mL of methanol and
injected into the LC-MS/MS instrument. Chromato -
graphic separation of 25(OH)D3 and 24,25(OH)2D3
and corresponding internal standards was achieved in
under 20 min using Kinetex F5 (150×4.6 mm, 2.6
mm, 100Å) LC column with corresponding guard col-
umn and isocratic mobile phase methanol: water (85:
15, v: v). Mobile phase flow was 0.3 mL/min and col-
umn temperature 20 °C. Quantification was done
using multiple-reaction-monitoring (MRM) on triple-
quad mass spectrometer Agilent 6420 equipped with
MMI/APCI ion source. The following m/z transitions
were used for quantification of the corresponding
metabolites and internal standards: 383.3 115,
105.1 for 25(OH)D3, 381.2 14 1.1, 105.2 for
24,25(OH)2D3, 389.37 115.2, 105.3 for 25(OH)
D3-d6 and 405.37  105 for 1,25(OH)2D3-d6. 
7-dehydrocholesterol was quantified by another
LC-MS/MS method developed and validated in our
laboratory. 100 mL was mixed with internal standard
and 1 mL of 2% potassium hydroxide in ethanol, vor-
texed and incubated for 30 min at 45 °C. Afterwards,
500 mL of water was added and 2 mL of n-hexane.
After vortexing and centrifugation (1500xg for 5
min), organic layer was separated. After collecting
and combining three organic layers into one reaction
tube, the extract was dried under nitrogen. Prior the
analysis, the extract was reconstituted in 100 mL of
methanol. Poroshell 120 EC-C18 column (4.6×150
mm, 2.7 mm) with corresponding guard column, and
isocratic mobile phase containing acetonitrile: metha -
nol: water (80: 18: 2, v: v: v) were used for chromato-
graphic separation. 7-dehydrocholesterol and internal
standard were eluted in 30 min runtime. The follow-
ing m/z transitions were used for quantification of the
7-DHC and cholesterol-26,26,26,27,27,27-d6:
367.3  131.3, 105.3 and 375.3  105.2, 95.2, respe -
ctively. Quantification was done using multiple-reac-
tion-monitoring (MRM) on triple quad mass spec-
trometer Agilent 6420 equipped with MMI/APCI ion
source.
Statistical analysis
Normality of data was tested by the Shapiro–
Wilk test. Normally distributed variables are presented
as means ± standard deviation, while asymmetrically
distributed data as median (interquartile range).
Categorical data are presented as absolute frequen-
cies and analyzed by the Chi-square test. For compar-
ison of continuous data with normal and asymmetri-
cal distribution were used Student t-test and
Mann-Whitney U-test, respectively. Comparison of
data stratified according to tumor grades was per-
formed by Kruskal-Wallis test. Correlation analysis
was performed by using Spearman correlation coeffi-
cients. Univariate logistic regression was employed for
detection of significant predictors of CRC develop-
ment and tumor grade. Adjustment in multivariate
logistic regression analysis was made for age, gender
and BMI (Model 1) and for age, gender, BMI and TC
level (Model 2). For statistical analysis we used IBM®
SPSS® model 22.0. Differences were considered sig-
nificant if P <0.05.
Results
General characteristics of the examined groups
are presented in Table I. Patients were older than con-
trols. Nevertheless, there were no significant correla-
tions between age and 25(OH)D3, 24,25(OH)2D3, 7-
DHC, VDMR, VDBP in control group (r=-0.051,
P=0.659; r=0.016, P=0.891; r=-0.056, P=0.632;
r=-0.099, P=0.390; r=-0.172, P=0.197, respec-
tively) nor in the patient group (r=-0.162, P=0.152;
r=-0.184, P=0.102; r=-0.135, P=0.233; r=-
0.111, P=0.326; r=-0.155, P=0.230, respectively).
Additionally, we divided both cohorts (patients and con-
trols) into quartiles according to age and also found no
statistically significant differences in all of the vitamin
D-related parameters between these quartiles (data not
shown). Male sex was more prevalent in the CRC
group. BMI and total proteins concentrations were sig-
nificantly lower in CRC patients. Our results demon-
strated a significant decrease in TC, LDL-C and HDL-C
concentrations in patients with CRC when compared to
healthy individuals. Levels of TG were comparable
among the groups. 
Next we analyzed differences in markers of vita-
min D status. Concentrations of 7-DHC were lower in
CRC patients, as well as levels of 25(OH)D3. In addi-
tion, the patients had lower levels of VDBP. We did not
find significant differences, although we recorded
lower levels of 24,25(OH)2D3 in CRC group. Finally,
values of VDMR were decreased in patients (Table I).
In order to check the influence of seasonal vari-
ations and exposure to UV light on markers of vitamin
D status, we divided both patients and controls in two
subgroups, according to the season when blood sam-
ples were collected (winter season from November to
April, or summer season from May to October). The
results are presented in Table II. None of the exam-
ined markers in patients differed with respect to sea-
son when samples are taken. On the other hand, in
the control group we found significantly higher con-
centrations of 25(OH)D3 and 24,25(OH)2D3 in sub-
jects who were included in study during the season
with higher exposure to UV light.
Analysis of vitamin D status parameters in
patients with different tumor grades (Table III)
demonstrated a decrease in concentrations of
25(OH)D3 alongside with the increase of tumor
grade, with statistical significance reached between
grade I and grade II. In contrast, concentration of
24,25(OH)2D3 was significantly higher in subjects
with tumor grade II when compared to patients with
well differentiated tumors. We found no significant
differences in TC concentration among patients with
tumor grades I-III. 
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Table I General characteristics and parameters of vitamin D status in study groups.
Values are presented as median (interquartile range) and compared by the Mann-Whitney U-test.
*Values are presented as mean ± standard deviation and compared by the Student t-test.
#Values are presented as absolute frequencies and compared by the Chi-square test.
Parameter CRC patients (N=82) Controls (N=77) P
Age (years)* 64.51±10.89 54.09±7.73 <0.001
Gender (male/female)# 58/24 44/33 0.098
BMI (kg/m2)* 25.20±3.28 26.35±3.72 0.030
Total protein (g/L)* 65.87±6.91 73.40±6.95 <0.001
TC (mmol/L) 4.43 (3.68–4.97) 5.62 (4.63–6.38) <0.001
LDL-C (mmol/L) 2.81 (2.13–3.20) 3.64 (2.88–4.33) <0.001
HDL-C (mmol/L) 0.99 (0.79–1.18) 1.23 (0.95–1.53) <0.001
TG (mmol/L) 1.22 (0.99–1.43) 1.31 (1.04–1.68) 0.316
7-DHC (mmol/L) 1.24 (0.91–1.94) 1.75 (1.23–2.56) 0.002
25(OH)D3 (ng/mL) 15.93 (12.04–22.18) 18.98 (15.85–23.75) 0.003
24,25(OH)2D3 (ng/mL) 2.98 (2.54–3.62) 3.26 (2.70–4.00) 0.135
VDMR 5.12 (4.49–6.17) 5.55 (4.84–6.66) 0.016
VDBP (mg/mL) 265.66 (210.45–332.68) 300.56 (258.12–342.88) 0.030
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In the next step, we explored correlations of vita-
min D status markers with other determined parame-
ters. Spearman correlation analysis did not revealed
any significant correlations between vitamin D status
markers and anthropometric measures or protein lev-
els (data not shown). Regarding relationship with
serum lipid levels, we found significant positive corre-
lations between TC concentration and levels of 7-
DHC (r=0.347; P<0.01), 25(OH)D3 (r=0.245;
P<0.05) and 24,25(OH)2D3 (r=0.295; P<0.01) in
CRC patients. In addition, significant positive correla-
tion was observed between LDL-C and 7-DHC
(r=0.293; P<0.01) and 25(OH)D3 (r=0.238;
P<0.05). Regarding the control group, positive asso-
ciation of TG concentration with 7-DHC was recorded
(r=0.331; P<0.01).
To further explore the observed associations of
TC with markers of vitamin D status, we stratified CRC
patients according to median values of TC concentra-
tions. The results of comparison of vitamin D status
markers between the two groups of patients with dif-
ferent TC levels are presented in Table IV. We
observed significantly higher levels of 7-DHC,
25(OH)D3 and 24,25(OH)2D3 in a group of CRC
patients with higher concentrations of TC. On the
other hand, values of VDMR and VDBP did not signif-
icantly differ among groups.
Finally, we examined a capacity of explored vita-
min D metabolites and VDBP for possible use as
Table II Seasonal effects on parameters of vitamin D status.
Table III TC and parameters of vitamin D status according to CRC grade.
Table IV Changes in parameters of vitamin D status accord-
ing to TC concentration in CRC patients.
Values are presented as median (interquartile range) and compared by the Mann-Whitney U-test.
Parameter










7-DHC (mmol/L) 1.28 (0.47–2.13) 1.24 (0.91–1.93) 0.918 1.61 (1.05–2.27) 1.90 (1.39–2.79) 0.125
25(OH)D3 (ng/mL) 16.13 (12.41–22.92) 15.98 (10.61–21.66) 0.618 22.54 (16.37–31.40) 18.33 (15.04–22.28) 0.023
24,25(OH)2D3
(ng/mL) 3.13 (2.61–4.26) 2.84 (2.61–3.67) 0.408 3.55 (3.04–5.38) 3.15 (2.62–3.74) 0.005
VDMR 5.12 (4.52–6.10) 5.09 (4.41–6.36) 0.925 5.53 (4.83–6.63) 5.70 (4.90–6.76) 0.738
VDBP (mg/mL) 266.94 (220.45–340.80) 260.13 (246.49–336.02) 0.797 334.28 (232.42–389.63) 296.60 (259.86–334.28) 0.352
Values are presented as median (interquartile range) and compared by the Kruskal-Wallis test and post hoc Mann-Whitney test.
a – significantly different from Grade I
*P<0.050; **P<0.01.
Parameter Grade I Grade II Grade III P
TC (mmol/L) 4.23 (3.44–5.23) 4.34 (3.75–4.80) 4.48 (3.65–5.03) 0.705
7-DHC (mmol/L) 1.25 (1.06–2.14) 1.23 (0.94–1.81) 0.79 (0.79–1.81) 0.563
25(OH)D3 (ng/mL) 19.66 (15.74–25.06) 14.77 (10.31–19.09)a** 14.27 (11.96–18.90) <0.050
24,25-(OH)2D3 (ng/mL) 3.11 (2.76–4.20) 3.18 (2.50–3.45) a* 2.93 (2.61–3.86) <0.050
VDMR 5.68 (4.66–7.18) 4.78 (3.90–5.60) 4.74 (4.46–5.20) 0.143
VDBP (mg/mL) 266.94 (223.11–361.62) 260.13 (197.57–302.90) 306.51 (208.21–366.40) 0.380
Values are presented as median (interquartile range) and

























VDBP (mg/mL) 263.11 (209.07–326.94)
269.06 
(210.77–343.53) 0.741
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markers of CRC risk prediction (Table V). Univariate
logistic regression analysis revealed that low levels of
25(OH)D3, 24,25(OH)2D3 and VDMR have signifi-
cant potential for prediction of CRC development,
while 25(OH)D3 retained its significance after the
adjustment for traditional risk factors (age, male sex
and BMI). However, after the inclusion of TC concen-
tration in the Model 2, 25(OH)D3 lost its predictive
potential. On the other hand, TC concentration was
recognized as potential significant predictor of CRC in
combination with traditional risk factors and
25(OH)D3 (OR: 0.417; CI: 0.267–0.650; P<0.001),
24,25(OH)2D3 (OR: 0.409; CI: 0.262–0.637;
P<0.001), and VDMR (OR: 0.404; CI: 0.259–0.629;
P<0.001). 
Similar analysis was performed to explore poten-
tial of vitamin D status parameters in prediction of
tumor grade. Patients are stratified in two cohorts:
subjects with low grade tumor (grade I) and subjects
with high grade tumor (grade II + grade III). Our
results (Table VI) demonstrated that only 25(OH)D3
was a significant risk factor for high grade carcinoma
development. In contrast to previous analysis, the
observed significance retained after adjustment for
other cofounders (age, male sex and BMI) and even
after inclusion of TC in the model.
Discussion
In this study, we demonstrated that concentra-
tions of 7-DHC, 25(OH)D3 and VDMR were de -
creased in CRC patients. 25(OH)D3 emerged as the
most prominent marker of changed vitamin D status
in CRC patients, as well as the molecule with the
highest potential for prediction of CRC development.
However, its predictive potential was abolished when
TC, as a routine lipid status marker, was included in
the analysis.
It is well known that status of vitamin D is dimin-
ished in patients with CRC (3). Our results (Table I)
support these findings. We observed a decrease in
concentrations of 7-DHC, 25(OH)D3 and VDBP, but
no differences between patients and controls were
recorded for 24,25(OH)2D3 (Table I). It is widely
accepted that seasonal variations in sun exposure are
major contributors to the vitamin D status (13), which
was also confirmed by the results in our healthy
cohort (Table II). However, when we analyzed vitamin
D metabolites in CRC patients, we did not find any
differences that could be attributed to the seasonal
variations in sun exposure. Therefore, our results sug-
gest that lower vitamin D status in CRC patients is
more likely a consequence of processes related to the
disease itself, than a result of reduced sun exposure.
Metabolic processing of vitamin D is complex
and not solely limited to liver and kidney. Instead,
extrarenal tissues, including colon, are active sites of
vitamin D metabolism (14). Namely, it has been
Table V Logistic regression analysis for evaluation of
parameters of vitamin D status in prediction of risk for
CRC development.
Table VI Parameters of vitamin D status in prediction of high
grade tumor development.
Model 1: adjustment was made for age, gender (m/f) and BMI.
Model 2: adjustment was made for age, gender (m/f), BMI and
TC.
Univariate logistic regression
Parameter OR 95% CI (OR) P
7-DHC (mmol/L) 0.926 (0.762–1.124) 0.437
25(OH)D3 (ng/mL) 0.934 (0.892–0.979) 0.004
24,25(OH)2D3 0.701 (0.514–0.956) 0.025
VDMR 0.769 (0.604–0.980) 0.034
VDBP (mg/mL) 0.997 (0.993–1.001) 0.115
Multivariate logistic regression
Model 1
Parameter OR 95% CI (OR) P
25(OH)D3 (ng/mL) 0.943 (0.893–0.996) 0.035
24,25(OH)2D3 0.714 (0.498–1.025) 0.068
VDMR 0.837 (0.613–1.144) 0.264
Model 2
Parameter OR 95% CI (OR) P
25(OH)D3 (ng/mL) 0.967 (0.912–1.025) 0.263
24,25(OH)2D3 0.807 (0.558–1.168) 0.256
VDMR 0.936 (0.669–1.310) 0.701
Model 1: adjustment was made for age, gender (m/f) and BMI.
Model 2: adjustment was made for age, gender (m/f), BMI and
TC.
Univariate logistic regression
Parameter OR 95% CI (OR) P
7-DHC (mmol/L) 1.040 (0.811–1.334) 0.756
25(OH)D3 (ng/mL) 0.911 (0.845–0.983) <0.05
24,25(OH)2D3 0.548 (0.301–0.999) 0.050
VDMR 0.734 (0.527–1.023) 0.068
VDBP (mg/mL) 0.997 (0.992–1.002) 0.281
Multivariate logistic regression
Model 1
Parameter OR 95% CI (OR) P
25(OH)D3 (ng/mL) 0.895 (0.822–0.975) <0.050
Model 2
Parameter OR 95% CI (OR) P
25(OH)D3 (ng/mL) 0.898 (0.823–0.979) <0.050
demonstrated that both CYP27B1, an enzyme
responsible for synthesis of active vitamin D form, and
CYP24A1, responsible for synthesis of inactive
24,25(OH)2D3 metabolite, are present in colono-
cytes and regulated by the level of cell’s differentia-
tion (14). Since previous researches confirmed
enhanced activity of CYP24A1 in less differentiated
colon cancer cells (14, 15), it would be expectable
to find increased concentrations of 24,25(OH)2D3
in systemic circulation of CRC patients. However,
our results did not show any differences in
24,25(OH)2D3 serum levels between patients and
controls (Table I). Yet, it is important to notice that
evidences regarding increased CYP24A1 and
24,25(OH)2D3 are derived from studies on cancer
tissue and cells, but not from analyses in serum. Since
blood levels of vitamin D metabolites are a reflection
of metabolic processes in numerous tissues, but prin-
cipally in liver and kidney, the influence of altered
metabolism in cancer cells might not be sufficient to
change serum concentration of a particular metabo-
lite. However, eventual broad use of vitamin D meta -
bolites for prediction and prognosis of CRC develop-
ment would likely be oriented toward serum or
plasma samples. Our results (Table I) suggest that
24,25(OH)2D3 might not be a reliable marker for
these purposes. In addition, although 24,25(OH)2D3,
alongside with 7-DHC were recognized as independ-
ent predictors of CRC in an univariate analysis, adjust-
ment for age, gender and BMI abolished their prog-
nostic capacity (Table V), thereby confirming the
above mentioned presumption. On the other hand,
VDMR was significantly lower in patients (Table I), but
such finding most likely reflected the presence of sig-
nificant differences in 25(OH)D3 concentrations,
thus emphasizing the importance of this vitamin D
metabolite.
It has been shown that vitamin D metabolism in
malignant cells is influenced by the extracellular avail-
ability of its active form and subsequent interaction
with vitamin D receptors (16). Also, previous studies
have demonstrated that the activity of CYP27B1 and
CYP24A1 depends on availability of substrate
25(OH)D3 (17, 18). Accordingly, overall amount of
25(OH)D3 is responsible for local activation and
effects of vitamin D. In our study, serum 25(OH)D3
and 7-DHC were significantly lower in CRC patients
(Table I), thereby setting prerequisites for later defec-
tive vitamin D activation and biological function in
extrarenal tissues. In parallel with low levels of vitamin
D precursors, we also observed a decrease in TC,
LDL-C and HDL-C levels (Table I). These findings
could be of particular importance, since vitamin D
and cholesterol share a common precursor: 7-DHC.
Previous studies of serum lipid levels in CRC are
inconsistent, but the findings similar to ours were
reported in the study of Abaza et al. (19). Apart from
poor nutritional status frequently seen in CRC (20),
which could be one of the reasons for decreased cho-
lesterol synthesis in the liver, it has been recently pro-
posed that reprogramming of lipid metabolism could
be responsible for the observed decrease in serum
lipid status markers in various types of cancer (20,
21). Namely, it has been demonstrated that cancer
cells extensively accumulate and use cholesterol (22,
23), while such increased needs are satisfied by either
upregulated endogenous synthesis (24), or enhanced
uptake of circulating cholesterol (25, 26). Such
rearrangement of cholesterol synthesis and cellular
accumulation could have important consequences
regarding vitamin D status. It has been proposed that
7-DHC is placed in the center of metabolic shift
between cholesterol and vitamin D synthesis path-
ways (7). In our study, lower levels of 7-DHC were
recorded in CRC patients (Table I). Thus, it is possible
that in conditions of increased utilization of choles-
terol by malignant cells and consequent generalized
direction of biosynthesis towards cholesterol, vitamin
D synthesis is compromised. In confirming such
assumption, we observed strong positive correlation
of serum levels of TC, LDL-C and HDL-C with 7-DHC
and analyzed vitamin D3 metabolites, but only in a
group of CRC patients. These findings suggest that
decreased serum cholesterol levels, which are indica-
tive for increased cholesterol utilization by malignant
cells, are associated with diminished vitamin D
synthe sis and further metabolic transformation.
Previously, Bogh et al. (26) have demonstrated that
elevation of 25(OH)D3 level after sun exposure was
in positive correlation with TC concentration. Thus,
local production of vitamin D in the skin can also be
compromised in the conditions of decreased serum
TC in CRC. Due to generalized lack of circulating cho-
lesterol, as seen in CRC, and consequent disabled
uptake by the other body structures apart from malig-
nant tissue, it would be reasonable to expect that
biosynthesis pathways in keratinocytes would likely be
directed towards cholesterol, rather than towards vita-
min D. Taken all together, our results might indicate
that decreased levels of vitamin D, regularly seen in
CRC, are in the first place a consequence of disturbed
lipid profile. Indeed, when we divided CRC patients
according to TC concentrations (Table IV), we found
lower values of 7-DHC, 25(OH)D3 and even
24,25(OH)2D3 in subjects with low TC, thereby con-
firming the impact of circulating cholesterol on all
aspects of vitamin D metabolism. 
Finally, when we explored independent potential
of vitamin D metabolites in predicting the risk for CRC
development (Table V), serum levels of 25(OH)D3
emerged as the most potent marker, whose relevance
was retained even after the adjustment for well-
known contributors of CRC development. However,
inclusion of TC concentration to the designed model,
eliminated the independent impact of decreased
25(OH)D3 on CRC development, which is in line with
the postulated role of TC in directing of vitamin D
metabolism. Interestingly, low serum TC was recog-
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nized as an independent predictor of CRC, emphasiz-
ing the role of lipid alterations in etiopathogenesis of
this disease. The role of lipids in cancer development
was neglected for a long time, but recent research
shed light on this topic (20). We have previously
demonstrated changed activity of lipid transfer pro-
teins (11) and alterations of lipoprotein subclasses
(12) in CRC patients. Possible influence on vitamin D
metabolites demonstrated herein can present an
additional effect of disturbed lipid homeostasis during
the development and progression of CRC.
Nevertheless, the role of vitamin D itself on the
tumor progression cannot be neglected. Namely, we
found a decrease in serum 25(OH)D3 levels across
tumor grades in parallel with an increase in
24,25(OH)2D3 in grade II CRC (Table III). The lack of
significant differences during comparison of grade III
subgroup with other subjects is most likely a conse-
quence of smaller number of participants in this
group. It is well known that vitamin D enhances cell
differentiation (1, 2), so the observed decrease of
25(OH)D3 in patients with poorly differentiated can-
cer is expected. More importantly, low 25(OH)D3
level was revealed as independent predictor of high
grade CRC, even after adjustment for other risk fac-
tors, including TC concentration (Table VI). There -
fore, our results suggest that 25(OH)D3 could be
useful as potential serum marker of increased risk for
high grade CRC, which should be further explored in
future studies. Data about the association between
vitamin D and tumor grade in CRC are scarce. Yet, it
has been recently demonstrated that expression of
nuclear vitamin D receptors gradually decreases dur-
ing the progression of low grade adenoma towards
high grade adenoma and CRC (27). Our findings
regarding serum vitamin D levels are in agreement
with these results. It also should be noticed that deter-
mination of serum 25(OH)D3 is a simple and inex-
pensive procedure, implying that vitamin D might be
considered as easily available and potentially useful
indicator of tumor grade in CRC patients.
It should also be mentioned that we observed
significantly lower VDBP levels in CRC patients when
compared to healthy participants (Table I). Such
results were expectable since VDBP is primarily syn-
thesized by the liver and it is well documented that
tumor-associated inflammation and production of
cytokines can decrease hepatic protein synthesis,
while on the other hand, malignant cells can increas-
ingly uptake serum proteins (28). Altogether, these
processes result in decreased total serum protein
which was also seen in our study (Table I). However,
our results did not demonstrate significant independ-
ent contribution of VDBP to the modulation of risk for
CRC development (Table V), which is in line with pre-
vious researches (28, 29), thus suggesting that the
impact of VDBP during CRC progression is more like-
ly indirect and related to vitamin D.
Several limitations should be emphasized. Due
to increased prevalence of CRC in older subjects and
limited possibilities to involve a sufficient number of
elderly healthy volunteers, patients and controls were
not completely matched by age. Although older age
is recognized as a significant contributor to lower vita-
min D status, in this study we found no differences in
vitamin D metabolites among different age groups.
However, our results should be further evaluated in
groups of patients and controls matched by age.
Patients and controls could not be matched
entirely by age for the purpose of this study.
Additionally, since this is an observational study, we
could not fully explore the presumed causality
between decreased TC level and minimized vitamin D
synthesis. Future researches for verifying our hypoth-
esis and elucidating possible mechanisms of these
interactions are needed. Next, cross-sectional nature
of our study prevented us from drawing conclusions
regarding the role of observed associations during the
progression of CRC. Forthcoming prospective studies
should address this topic.
Conclusions
In conclusion, our results demonstrated de -
creased levels of 7-DHC, 25(OH)D3 and VDMR in
patients with CRC. In addition, we observed a signifi-
cant positive association between vitamin D status
and serum lipid markers. Although 25(OH)D3 was
revealed as significant marker of CRC development,
the obtained results suggested profound impact of
serum cholesterol on the levels of vitamin D metabo-
lites and give a new perspective for understanding the
vitamin D deficiency in CRC, and possible improve-
ment of patient management strategies.
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